

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

11046 U.S. PTO  
 09/925641  
 11/10/01

In re PATENT APPLICATION of  
 Inventor(s): CRESSWELL et al.

Appln. No.:	to be	assigned
Series Code	↑	↑ Serial No.

Group Art Unit: to be assigned

Filed: August 10, 2001

Examiner: to be assigned

Title: Chemical Compounds

Atty. Dkt. P 0282794	100139/US
M#	Client Ref

Date: August 10, 2001

## SUBMISSION OF PRIORITY DOCUMENT IN ACCORDANCE WITH THE REQUIREMENTS OF RULE 55

Hon. Asst Commissioner of Patents  
 Washington, D.C. 20231

Sir:

Please accept the enclosed certified copy(ies) of the respective foreign application(s) listed below for which benefit under 35 U.S.C. 119/365 has been previously claimed in the subject application and if not is hereby claimed.


<u>Application No.</u>	<u>Country of Origin</u>	<u>Filed</u>
00 205 44.3	GB	August 22, 2000

Respectfully submitted,

Pillsbury Winthrop LLP  
 Intellectual Property Group

1600 Tysons Boulevard

McLean, VA 22102  
 Tel: (703) 905-2000  
 Atty/Sec: DJB/AMX

By Atty: <u>Donald J. Bird</u>	Reg. No. <u>25323</u>
Sig: 	Fax: (703) 905-2500 Tel: (703) 905-2018



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

j1046 U.S. PTO  
09/925641  
08/10/01

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein together with the Statement of inventorship and of right to grant of a Patent (Form 7/77), which was subsequently filed.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed


*Amstrong*

Dated

26 June 2001

# Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

100139

2. Patent application number

(The Patent Office will fill in this part)

0020544.3

22 AUG 2000

3. Full name, address and postcode of the or of each applicant (underline all surnames)

AstraZeneca AB

S-151 85 Sodertalje

Sweden

22 AUG 00 E562439-1 002934

P01/7700 0.00-0020544.3

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

7822448003

4. Title of the invention

CHEMICAL COMPOUNDS

5. Name of your agent (if you have one)

Allen Giles

6988463003

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

AstraZeneca UK Ltd

Global Intellectual Property Department - Patents

PO BOX 272, Mereside, Alderley Park

Macclesfield, Cheshire, SK10 4GR

England

Patents ADP number (if you know it)

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number  
(if you know it)

Date of filing  
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing  
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

### CHEMICAL COMPOUNDS

This invention relates to polymorphisms in the human MCT-1 gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the MCT-1 gene, and to the use of MCT-1 polymorphism in treatment of diseases with MCT-1 transportable drugs.

Monocarboxylic acids play a major role in the metabolism of all cells, with lactic acid, the end product of glycolysis, being especially important. Some tissues, such as white skeletal muscle, red blood cells and many tumour cells, rely on this pathway to produce most of their ATP under normal physiological conditions, while all tissues become dependent on this pathway during hypoxia or ischaemia. Glycolysis produces two molecules of lactic acid for every glucose molecule consumed, and these must be transported out of the cell if high rates of glycolysis are to be maintained. If efflux of lactic acid from the cell does not keep pace with production, intracellular concentrations increase and cause the pH of the cytosol to decrease. This leads to inhibition of phosphofructokinase and hence glycolysis. Other tissues, such as brain, heart and red skeletal muscle, readily oxidize lactic acid, which may become a major respiratory fuel under some conditions. In these tissues lactic acid must be rapidly transported into the cell. The same is true for tissues such as the liver, which, through the operation of the Cori cycle, utilise lactate as their dominant gluconeogenic substrate (Denton, R. M. and Halestrap, A. P. (1979) *Essays Biochem.* 15, 37-47; Juel, C. (1997) *Physiol. Rev.* 77, 321-358.) Although it is lactic acid that is both produced and utilized by metabolism, the pK of lactic acid is 3.86, which ensures that it dissociates almost entirely to the lactate anion at physiological pH. This charged species cannot cross the plasma membrane by free diffusion, but requires a specific transport mechanism, provided by proton-linked monocarboxylate transporters (MCTs). These transporters catalyse the facilitated diffusion of lactate with a proton. There is no energy input other than that provided by the concentration gradients of lactate and protons, although the latter, in the form of a pH gradient, can drive the accumulation or exclusion of the lactate anion (Poole, R. C. and Halestrap, A. P. (1993) *Am. J. Physiol.* 264, C761-C782.; Juel, C. (1997) *Physiol. Rev.* 77, 321-358).

MCT-1 is thought to be involved in the transport of drugs involved in lipid lowering e.g. statins. Statins have been referred to as a first-line therapy for patients with atherosclerotic vascular diseases.

The term human includes both a human having or suspected of having a MCT-1 mediated disease and an asymptomatic human who may be tested for predisposition or susceptibility to such disease. At each position the human may be homozygous for an allele or the human may be a heterozygote.

5 The term single nucleotide polymorphism includes single nucleotide substitution, nucleotide insertion and nucleotide deletion which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene.

In one embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 1450 is presence of A  
10 and/or G.

In one embodiment of the invention preferably the method for diagnosis described herein is one in which the single nucleotide polymorphism at position 1482 is presence of A and/or T.

In another embodiment of the invention preferably the method for diagnosis described  
15 herein is one in which the single nucleotide polymorphism at position 2461 is the presence of A and/or G.

The method for diagnosis is preferably one in which the sequence is determined by a method selected from amplification refractory mutation system and restriction fragment length polymorphism.

20 The status of the individual may be determined by reference to allelic variation at any one, two or three or more positions.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the  
25 sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant  
30 nucleotides at one or more polymorphic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation

**Hybridisation Based**

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots,  
Oligonucleotide arrays (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La  
5 Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO  
95/13399 (Public Health Inst., New York)

**Extension Based:** ARMS™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca  
Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

**Incorporation Based:** Mini-sequencing, APEX

10 **Restriction Enzyme Based:** RFLP, Restriction site generating PCR

**Ligation Based:** OLA

**Other:** Invader assay

Table 2 - Signal Generation or Detection Systems

15 **Fluorescence:** FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom  
Patent No. 2228998 (Zeneca Limited)

**Other:** Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric,  
Hybridisation protection assay, Mass spectrometry

20 Table 3 - Further Amplification Methods

SSR, NASBA, LCR, SDA, b-DNA

Preferred mutation detection techniques include ARMS™, ALEX™, COPS, Taqman,  
Molecular Beacons, RFLP, and restriction site based PCR and FRET techniques.

25 Particularly preferred methods include ARMS™ and RFLP based methods. ARMS™  
is an especially preferred method.

In a further aspect, the diagnostic methods of the invention are used to assess the  
pharmacogenetics of a drug transportable by MCT-1.

Assays, for example reporter-based assays, may be devised to detect whether one or  
30 more of the above polymorphisms affect transcription levels and/or message stability.

Individuals who carry particular allelic variants of the MCT-1 gene may therefore  
exhibit differences in their ability to regulate protein biosynthesis under different

According to another aspect of the present invention there is provided a human MCT-1 gene or its complementary strand comprising an allelic variant, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least 20 bases comprising at least one allelic variant.

5           Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

According to another aspect of the present invention there is provided an allele  
10 specific primer capable of detecting a MCT-1 gene polymorphism, preferably at one or more of the positions as defined herein.

An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as  
15 used for ARMS™ assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4,  
20 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology  
25 Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1<sup>st</sup> Edition. If required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting a MCT-1 gene polymorphism, preferably at one or more of the positions defined herein.

30           The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

disequilibrium at the cystathionine beta synthase (CBS) locus and the association between genetic variation at the CBS locus and plasma levels of homocysteine. *Ann Hum Genet* (1998) 62:481-90, De Stefano V, Dekou V, Nicaud V, Chasse JF, London J, Stansbie D, Humphries SE, and Gudnason V; and Variation at the von willebrand factor (vWF) gene locus is  
5 associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. *Blood* (1999) 93:4277-83, Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D).

According to another aspect of the present invention there is provided a computer readable medium comprising at least one novel sequence of the invention stored on the  
10 medium. The computer readable medium may be used, for example, in homology searching, mapping, haplotyping, genotyping or pharmacogenetic analysis.

According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug transportable by MCT-1 in which the method comprises:

- 15 i) diagnosis of a single nucleotide polymorphism in MCT-1 gene in the human, which diagnosis preferably comprises determining the sequence of the nucleic acid at one or more of the following positions:  
positions 1450, 1482 and 2461 in the sequence of the MCT-1 gene as defined by the position in SEQ ID NO: 13
- 20 and determining the status of the human by reference to polymorphism in the MCT-1 gene;  
and
- ii) administering an effective amount of the drug.

Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which statin drug or drugs to administer and/or in  
25 deciding on the effective amount of the statin drug or drugs. Statins already approved for use in humans include atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin. The reader is referred to the following references for further information: *Drugs and Therapy Perspectives* (12<sup>th</sup> May 1997), 9: 1-6; Chong (1997) *Pharmacotherapy* 17: 1157-1177; Kellick (1997) *Formulary* 32: 352; Kathawala (1991) *Medicinal Research Reviews*, 11: 121-146;  
30 Jahng (1995) *Drugs of the Future* 20: 387-404, and *Current Opinion in Lipidology*, (1997), 8, 362 - 368. Another statin drug of note is compound 3a (S-4522) in Watanabe (1997) *Bioorganic and Medicinal Chemistry* 5: 437-444. The term "drug transportable by MCT-1"



Examples of various assays useful for such determination include those described in:  
*Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays

5 (ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

Monoclonal antibodies may be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

10 The monoclonal antibodies of the invention can be produced using alternative techniques, such as those described by Altling-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3: 1-9 (1990) which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes  
15 a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7: 394 (1989).

Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to ELISA" by D. M. Kemeny, Pergamon Press, Oxford, England.

20 According to another aspect of the invention there is provided a diagnostic kit comprising an antibody of the invention.

The invention will now be illustrated but not limited by reference to the following Examples. All temperatures are in degrees Celsius.

In the Examples below, unless otherwise stated, the following methodology and  
25 materials have been applied.

AMPLITAQ™, available from Perkin-Elmer Cetus, is used as the source of thermostable DNA polymerase.

General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch  
30 and Maniatis (Cold Spring Harbor Laboratory, 1989).

For dye-primer sequencing these primers were modified to include M13 forward and reverse primer sequences (ABI protocol P/N 402114, Applied Biosystems) at the 5' end of the forward and reverse oligonucleotides respectively.

#### 5 MCT1 oligos for cDNA Amplification

Product 1F (13-32)	SEQ ID NO 1
Product 1R (559-578)	SEQ ID NO 2
Product 2F (429-448)	SEQ ID NO 3
Product 2R (948-967)	SEQ ID NO 4
Product 3F (778-797)	SEQ ID NO 5
Product 3R (1428-1409)	SEQ ID NO 6
Product 4F (1243-1262)	SEQ ID NO 7
Product 4R (1837-1818)	SEQ ID NO 8
Product 5F (1667-1786)	SEQ ID NO 9
Product 5R (2149-2130)	SEQ ID NO 10
Product 6F (2051-2070)	SEQ ID NO 11
Product 6R (2556-2537)	SEQ ID NO 12

F= forward, R= reverse

10

#### Dye Primer Sequencing

Dye-primer sequencing using M13 forward and reverse primers was as described in the ABI protocol P/N 402114 for the ABI Prism™ dye primer cycle sequencing core kit with "AmpliTaq FS" DNA polymerase, modified in that the annealing temperature was 45 °C and

15 DMSO was added to the cycle sequencing mix to a final concentration of 5%.

The extension reactions for each base were pooled, ethanol/sodium acetate precipitated, washed and resuspended in formamide loading buffer.

4.25% Acrylamide gels were run on an automated sequencer (ABI 377, Applied Biosystems).

20

25

CLAIMS

- 1 A method for the diagnosis of a single nucleotide polymorphism in MCT-1 in a human, which method comprises determining the sequence of the nucleic acid of the human at  
5 at least one polymorphic position selected from one or more of the following positions: positions 1450, 1482 and 2461 in the polynucleotide sequence of the MCT-1 gene as defined by the position in SEQ ID NO: 13; and determining the status of the human by reference to polymorphism in the MCT-1 gene.
- 2 A method according to claim one in which the single nucleotide polymorphisms are  
10 further defined as follows:  
at position 1450 is presence of A and/or G;  
at position 1482 is presence of A and/or T; and  
at position 2461 is the presence of A and/or G.
- 3 A method for diagnosis according to claim 1 or 2 in which the sequence is determined  
15 by a method selected from amplification refractory mutation system and restriction fragment length polymorphism.
- 4 A polynucleotide comprising at least 20 bases of the human MCT-1 gene and comprising an allelic variant selected from any one of the following:
- | variant | Position in SEQ ID NO 13 |
|---------|--------------------------|
| G       | 1450                     |
| T       | 1482                     |
| G       | 2461                     |
- 20 5 An allele specific primer capable of detecting a MCT-1 gene polymorphism at one or more of the positions as defined in claim 1.
- 6 An allele-specific oligonucleotide probe capable of detecting a MCT-1 gene polymorphism at one or more of the positions defined in claim 1.
- 7 A diagnostic kit comprising an allele specific oligonucleotide probe as defined in  
25 claim 6 and/or an allele-specific primer as defined in claim 5.
- 8 Use of a single nucleotide polymorphism as defined in claim 1 as a genetic marker in linkage studies.

ABSTRACT

TITLE:      **CHEMICAL COMPOUNDS**

5

This invention relates to polymorphisms in the human MCT-1 gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the MCT-1 gene, and to the use of MCT-1 polymorphism in treatment of diseases with MCT-1 transportable drugs.

10

15

## SEQUENCE LISTING

<110> AstraZeneca AB

5 <120> Chemical Compounds

<130> afg

<140>

10 <141>

<160> 13

<170> PatentIn Ver. 2.1

15 <210> 1

<211> 15

<212> DNA

<213> Artificial Sequence

20 <220>

<223> Description of Artificial Sequence:PCR primer

<400> 1

25 accagcagtt ggagg 15

<210> 2

<211> 15

30 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

35 <400> 2

gttagtagc aagcc 15

<210> 3

<211> 15

<212> DNA

<213> Artificial Sequence

40 <220>

<223> Description of Artificial Sequence:PCR primer

<400> 3

agaggcgacc attgg 15

50 <210> 4

<211> 15

<212> DNA

55 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

60 <400> 4

cccatagatg gtcgg 15

<210> 5

<211> 15  
<212> DNA  
<213> Artificial Sequence

5 <220>  
<223> Description of Artificial Sequence:PCR primer

<400> 5  
attcacccac agagg 15

10

<210> 6  
<211> 15  
<212> DNA  
15 <213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

20 <400> 6  
caacatctat actgg 15

<210> 7  
25 <211> 15  
<212> DNA  
<213> Artificial Sequence

<220>  
30 <223> Description of Artificial Sequence:PCR primer

<400> 7  
caatgacatg tatgg 15

35

<210> 8  
<211> 15  
<212> DNA  
<213> Artificial Sequence

40

<220>  
<223> Description of Artificial Sequence:PCR primer

<400> 8  
45 taaggctctc tagag 15

<210> 9  
<211> 15  
50 <212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence:PCR primer

55

<400> 9  
cttaccaata gcctg 15

60

<210> 10  
<211> 15  
<212> DNA  
<213> Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:PCR primer

&lt;400&gt; 10

5 gtgtctagaa cagcc

15

&lt;210&gt; 11

&lt;211&gt; 14

10 &lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

15 &lt;223&gt; Description of Artificial Sequence:PCR primer

&lt;400&gt; 11

agtagatttc tggc

14

20 &lt;210&gt; 12

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

25 &lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:PCR primer

&lt;400&gt; 12

30 cacatagcac taagc

15

&lt;210&gt; 13

&lt;211&gt; 2578

&lt;212&gt; DNA

35 &lt;213&gt; Homo sapiens

&lt;400&gt; 13

tctacactta aaatgccacc agcagttgga ggtccagttg gatacacccc cccagatgga 60  
 ggctggggct gggcagtggt aattggagct ttcatttcca tcggcttctc ttatgcattt 120  
 40 cccaaatcaa ttactgtctt cttcaaagag attgaaggta tattccatgc caccaccagc 180  
 gaagtgtcat ggatattcctc cataatgttg gctgtcatgt atgggtggagg tcctatcagc 240  
 agtatcctgg tgaataaata tggaaagtcgt atagtcatga ttgttgggtg ctgcttgatc 300  
 ggctgtggct tgattgcagc ttctttctgt aacaccgtac agcaactata cgtctgtatt 360  
 ggagtcattg gaggtcttgg gcttgccttc aacttgaatc cagctctgac catgattggc 420  
 45 aagtatttct acaagaggcg accattggcc aacggactgg ccatggcagg cagccctgtg 480  
 ttctctgtga ctctggcccc cctcaatcag gttttcttcg gtatcttttg atggagagga 540  
 agctttttaa ttcttggggg cttgctacta aactgctgtg ttgctggagc cctcatgcca 600  
 ccaatcgggc ccaagccaac caaggcaggg aaagataagt ctaaagcatc ccttgagaaa 660  
 gctggaaaat ctggtgtgaa aaaagatctg catgatgcaa atacagatct tattggaaga 720  
 50 caccctaaac aagagaaacg atcagtcctt caaacaatta atcagttcct ggacttaacc 780  
 ctattcacc acagaggctt tttgctatac ctctctggaa atgtgatcat gttttttgga 840  
 ctctttgcac ctttgggtgtt tcttagtagt tatgggaaga gtcagcatta ttctagttag 900  
 aagtctgcct tcttctttt cattctggct tttgttgaca tggtagcccc accatctatg 960  
 ggacttttag ccaacacaaa gccaataaga cctcgaattc agtatttctt tgcggcttcc 1020  
 55 gtttattgcaa atggagtgtg tcatatgcta gcaccttat ccactaccta tgttggattc 1080  
 tgtgtctatg cgggattctt tggatttgcc ttcgggtggc tcagctccgt attgtttgaa 1140  
 acattgatgg accttgttgg accccagagg ttctccagcg ctgtgggatt ggtgaccatt 1200  
 gtggaatgct gtcctgtcct cctggggcca ccacttttag gtcggctcaa tgacatgtat 1260  
 ggagactaca aatacacata ctgggcatgt ggcgtcgtcc taattatttc aggtatctat 1320  
 60 ctcttcattg gcatgggcat caattatcga cttttggcaa aagaacagaa agcaaacgag 1380  
 cagaaaaagg aaagtaaaaga ggaagagacc agtatagatg ttgctgggaa gccaaatgaa 1440  
 gttacacaaa cagcagaatc tccggaccag aaagacacag aaggaggggc caaggaggag 1500  
 gaaagtccag tctgaatcca tggggctgaa gggtaaatg agcagtcat gaccaggat 1560  
 atctgaaaat attctactgg cctgtaatct accagtggtg ctcaatgcaa atagtagaca 1620

tttgtgtgga aatcatacca gttgttcatt gatgggattt ttgtttgact ccttaccaat 1680  
 agcctgaatt tgaggaggga atgattggta gcaaaggatg ggggaaagaa gtaggttctg 1740  
 ttttgttttg ttttaatctt agcttttaat agtgtcataa agattataat atgtgcctta 1800  
 agtttttagtc ttttagaactc tagagagcct taactttctta aaccattttt gctgaattca 1860  
 5 tctatttcga grgttggtgtt aaaaggaaaa ataacaacta acttggtttga ggcaaatcta 1920  
 aaatttaaaa ttaatcttgc ttcattgtta catgtaatat atttcagaca ttttcaactgg 1980  
 aagatttattg aacagaaaata ttggttgaaa gttagagatt ttacaaaatg ctgacaaaaa 2040  
 tattttccta gcatcagtag atttctggca tatgtttctg ctagctatat atttaggaaa 2100  
 ttcaaagcat aaaactttgg caacatcttg gctgttctag acacagtgtg cttgtcaacc 2160  
 10 cctctcaggt accttttctt gggatgctta ttagaagcca agtaaagtgc ttaagggttg 2220  
 ttttcattaa attagctatt tctgctcccc tgttcaaaga tgcattttga gtgtttatag 2280  
 atcactgccc tttttgaaat cacctgggtat tatttttctt actggaaaag ttagtattaa 2340  
 aatctacaga actaacatatt tgtgcctcct tggtaaatac aacacatcta attaaatgta 2400  
 gacagatatt tcaaacatca gctgaattca ctttaagttt tccaaaacct cagttaaact 2460  
 15 gtgaagctat tgggaattttt ttttctggga atttttcccc tttgattcac agtggtccca 2520  
 tttatatctg cttctagctt agtgctatgt gtgagatatg tgtgtgttg gtgtttt 2578

20 <210> 14  
 <211> 500  
 <212> PRT  
 <213> Homo sapiens

25 <400> 14  
 Met Pro Pro Ala Val Gly Gly Pro Val Gly Tyr Thr Pro Pro Asp Gly  
 1 5 10 15

30 Gly Trp Gly Trp Ala Val Val Ile Gly Ala Phe Ile Ser Ile Gly Phe  
 20 25 30

Ser Tyr Ala Phe Pro Lys Ser Ile Thr Val Phe Phe Lys Glu Ile Glu  
 35 40 45

35 Gly Ile Phe His Ala Thr Thr Ser Glu Val Ser Trp Ile Ser Ser Ile  
 50 55 60

Met Leu Ala Val Met Tyr Gly Gly Gly Pro Ile Ser Ser Ile Leu Val  
 65 70 75 80

40 Asn Lys Tyr Gly Ser Arg Ile Val Met Ile Val Gly Gly Cys Leu Ser  
 85 90 95

45 Gly Cys Gly Leu Ile Ala Ala Ser Phe Cys Asn Thr Val Gln Gln Leu  
 100 105 110

Tyr Val Cys Ile Gly Val Ile Gly Gly Leu Gly Leu Ala Phe Asn Leu  
 115 120 125

50 Asn Pro Ala Leu Thr Met Ile Gly Lys Tyr Phe Tyr Lys Arg Arg Pro  
 130 135 140

Leu Ala Asn Gly Leu Ala Met Ala Gly Ser Pro Val Phe Leu Cys Thr  
 145 150 155 160

55 Leu Ala Pro Leu Asn Gln Val Phe Phe Gly Ile Phe Gly Trp Arg Gly  
 165 170 175

60 Ser Phe Leu Ile Leu Gly Gly Leu Leu Leu Asn Cys Cys Val Ala Gly  
 180 185 190

Ala Leu Met Arg Pro Ile Gly Pro Lys Pro Thr Lys Ala Gly Lys Asp  
 195 200 205



Lys Ser Lys Ala Ser Leu Glu Lys Ala Gly Lys Ser Gly Val Lys Lys  
 210 215 220  
 5 Asp Leu His Asp Ala Asn Thr Asp Leu Ile Gly Arg His Pro Lys Gln  
 225 230 235 240  
 Glu Lys Arg Ser Val Phe Gln Thr Ile Asn Gln Phe Leu Asp Leu Thr  
 245 250 255  
 10 Leu Phe Thr His Arg Gly Phe Leu Leu Tyr Leu Ser Gly Asn Val Ile  
 260 265 270  
 Met Phe Phe Gly Leu Phe Ala Pro Leu Val Phe Leu Ser Ser Tyr Gly  
 275 280 285  
 15 Lys Ser Gln His Tyr Ser Ser Glu Lys Ser Ala Phe Leu Leu Ser Ile  
 290 295 300  
 20 Leu Ala Phe Val Asp Met Val Ala Arg Pro Ser Met Gly Leu Val Ala  
 305 310 315 320  
 Asn Thr Lys Pro Ile Arg Pro Arg Ile Gln Tyr Phe Phe Ala Ala Ser  
 325 330 335  
 25 Val Val Ala Asn Gly Val Cys His Met Leu Ala Pro Leu Ser Thr Thr  
 340 345 350  
 Tyr Val Gly Phe Cys Val Tyr Ala Gly Phe Phe Gly Phe Ala Phe Gly  
 355 360 365  
 30 Trp Leu Ser Ser Val Leu Phe Glu Thr Leu Met Asp Leu Val Gly Pro  
 370 375 380  
 35 Gln Arg Phe Ser Ser Ala Val Gly Leu Val Thr Ile Val Glu Cys Cys  
 385 390 395 400  
 Pro Val Leu Leu Gly Pro Pro Leu Leu Gly Arg Leu Asn Asp Met Tyr  
 405 410 415  
 40 Gly Asp Tyr Lys Tyr Thr Tyr Trp Ala Cys Gly Val Val Leu Ile Ile  
 420 425 430  
 Ser Gly Ile Tyr Leu Phe Ile Gly Met Gly Ile Asn Tyr Arg Leu Leu  
 435 440 445  
 45 Ala Lys Glu Gln Lys Ala Asn Glu Gln Lys Lys Glu Ser Lys Glu Glu  
 450 455 460  
 50 Glu Thr Ser Ile Asp Val Ala Gly Lys Pro Asn Glu Val Thr Lys Thr  
 465 470 475 480  
 Ala Glu Ser Pro Asp Gln Lys Asp Thr Glu Gly Gly Pro Lys Glu Glu  
 485 490 495  
 55 Glu Ser Pro Val  
 500

&lt;210&gt; 15

&lt;211&gt; 22

60 &lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence:PCR primer

<400> 15  
ctccggacca gaaagacaca gc  
5  
<210> 16  
<211> 20  
<212> DNA  
<213> Artificial Sequence  
10  
<400> 16  
gaagttaagg ctctctagag

22

20